Clinical trial NCT03472586: Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Official title: Ipilimumab and Nivolumab in Combination With Immunoembolization for the Treatment of Metastatic Uveal Melanoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Metastatic Malignant Neoplasm in the Liver
Metastatic Uveal Melanoma
Stage IV Uveal Melanoma AJCC v7
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
Collaborators: name: Bristol-Myers Squibb
First posted: 2018-03-21
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase II trial studies ipilimumab and nivolumab with immunoembolization in treating patients with uveal melanoma that has spread to the liver. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunoembolization may kill tumor cells due to loss of blood supply and develop an immune response against tumor cells. Giving ipilimumab and nivolumab with immunoembolization may work better in treating patients with uveal melanoma.

Detailed description: PRIMARY OBJECTIVES:

I. Determine the clinical benefit of treatment with immunoembolization (IEMBO) in combination with ipilimumab and nivolumab.

SECONDARY OBJECTIVES:

I. Determine all treatment and immune related toxicities. II. Determine progression free survival. III. Determine overall survival.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed metastatic uveal melanoma in the liver; patients must have at least one measurable liver metastasis that is \>= 10 mm in longest diameter by computed tomography (CT) scan or magnetic resonance imaging (MRI)
* The total volume of the tumors must be less than 50% of the liver volume
* Willingness and ability to give informed consent
* Agreement to access archival tissue or agreement for tumor biopsy prior to treatment
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1
* Serum creatinine =\< 2.0 mg/dl
* Granulocyte count \>= 1000/mm\^3
* Platelet count \>= 100,000/mm\^3
* Bilirubin =\< 2.0 mg/ml
* Albumin \>= 3.0 g/dl
* Prothrombin time (PT)/partial thromboplastin time (PTT) less than 1.5 times normal
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 x upper limit of normal (ULN)
* Alkaline phosphatase less than 1.5 times ULN (grade 1)
* Women must not be pregnant or breast-feeding
* Women of child-bearing potential must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 23 weeks after the last dose of nivolumab and/or ipilimumab and sexually active males must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 31 weeks after the last dose of nivolumab and/or ipilimumab

Exclusion Criteria:

* Failure to meet any of the criteria set forth in the inclusion criteria section
* Previous systemic exposure to anti-CTLA-4 antibody or anti-PD1 antibody
* Previous liver-directed treatments including chemoembolization, radiosphere, hepatic arterial perfusion, or drug-eluting beads; liver resection and focal ablation are permitted
* Presence of symptomatic liver failure including ascites and hepatic encephalopathy
* Presence of untreated brain metastases; if patients have had previous treatment for the brain metastasis, an MRI or CT scan of the brain must confirm the stabilization of the brain metastasis for more than 2 months
* Presence of uncontrolled hypertension or congestive heart failure, or acute myocardial infarction within 6 months of entry
* Presence of any other medical complication that implies survival of less than six months
* Uncontrolled severe bleeding tendency or active gastrointestinal (GI) bleeding
* Significant allergic reaction to contrast dye or granulocyte-macrophage colony-stimulating (GM-CSF)
* Immunosuppressive treatments within 4 weeks prior to embolization, unless prednisone =\< 5 mg or equivalent
* Pregnancy or breast-feeding women
* Patients with active hepatitis with serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) equal or greater than 5 times normal
* Biliary obstruction, biliary stent or prior biliary surgery except cholecystectomy
* Positive for known human immunodeficiency virus (HIV) Infection
* Uncontrolled chronic obstructive pulmonary disease or previous known pulmonary fibrosis
* Active infection
* Auto-immune disease including inflammatory bowel disease, lupus, rheumatoid arthritis, but not including hypothyroidism or psoriasis if condition has been stable for 2 months or greater

Primary outcomes:
measure: Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
timeFrame: At the end of 4th treatment cycle (Day 84 +/- 3 days). Cycles are 21 days.
Secondary outcomes:
measure: Incidence of Adverse Events
timeFrame: Up to 1 year
measure: Progression Free Survival (PFS)
timeFrame: From the start of the treatment to confirmation of progression of disease, assessed up to 1 year
measure: Overall Survival
timeFrame: From the start of the treatment to confirmation of progression of disease, assessed up to 1 year
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Sidney Kimmel Cancer Center at Thomas Jefferson University
state: Pennsylvania
Study officials:
affiliation: Sidney Kimmel Cancer Center at Thomas Jefferson University
name: Marlana Orloff, MD
role: PRINCIPAL_INVESTIGATOR
References: